Researchers review the future of schizophrenia treatment, highlighting TAAR1 agonists, NMDA enhancers, and the gut-brain axis ...

A finding by a McGill-led team of neuroscientists could open doors to new treatments for a range of psychiatric and neurological disorders attributed to dysfunctions in specific dopamine pathways. For ...

Our understanding of schizophrenia has increased greatly in recent years, as studies of large groups of people have identified a multitude of genetic variants that increase a person's risk of the ...

The caudate nucleus (green) is a subcortical brain region located in the striatum. The striatum is one of several neural structures that make up the basal ganglia (colored regions) located below the ...

The U.S. Food and Drug Administration approved Cobenfy on September 26, 2024, making it the first schizophrenia drug with a fundamentally new mechanism of action in more than half a century. Built on ...

Prof. Alex Nord, right and graduate student Tracy Warren have discovered genetic variants linked to some symptoms of schizophrenia that are currently hard to treat. The work could lead to new insights ...

Dopamine is one of the most extensively studied chemical messengers in the human brain, and yet scientists are still figuring out how it works to accomplish so much. For years, the classic view has ...

A McGill University-led study found that people with cannabis use disorder (CUD) had elevated dopamine levels in a brain region associated with psychosis. “This could help explain why cannabis use ...

Psychiatry has spent decades focused on dopamine, serotonin, norepinephrine, and glutamate. These key neurotransmitters – known to regulate mood, behaviour, and bodily functions – have served as the ...